2023 Annual Meeting | C63 - Myelopathies: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes
03:30 PM - 03:35 PM EST | Introduction |
Introduction
Eoin P. Flanagan, MBBCh, FAAN |
03:35 PM - 04:10 PM EST | Speaker |
Inflammatory Myelopathies; Clinical, Serologic, and Treatment Pearls
Jacqueline Palace |
04:10 PM - 04:45 PM EST | Speaker |
Radiologic Pearls in Vascular and Inflammatory Myelopathies and Their Mimics
Eoin P. Flanagan, MBBCh, FAAN |
04:45 PM - 05:20 PM EST | Speaker |
Clinical Pearls in Vascular Myelopathies
Neeraj Kumar, MD |
05:20 PM - 05:30 PM EST | Discussion |
Questions and Answers
Eoin P. Flanagan, MBBCh, FAAN, Neeraj Kumar, MD, Jacqueline Palace |
Neeraj Kumar, MD | Dr. Kumar has nothing to disclose. |
Jacqueline Palace | Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, AMgen, UCB, Roche, Novartis, Amplo, Alexion, . Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Amgen. Dr. Palace has stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,. argenx, amgen. Dr. Palace has received intellectual property interests from a discovery or technology relating to health care. |
Eoin P. Flanagan, MBBCh, FAAN | The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. |